Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis

CD14, a high-affinity receptor for lipopolysaccharide (LPS), is a glycoprotein expressed on the surface membranes of monocytes/macrophages. We have identified a previously unknown form of soluble CD14, named soluble CD14 subtype (sCD14-ST), that is increased in patients with sepsis. To measure sCD14...

Full description

Saved in:
Bibliographic Details
Published inJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy Vol. 11; no. 5; pp. 234 - 238
Main Authors Yaegashi, Yasunori, Sato, Nobuhiro, Suzuki, Yasushi, Kojika, Masahiro, Imai, Satoko, Takahashi, Gaku, Miyata, Michiko, Endo, Shigeatsu, Shirakawa, Kamon, Furusako, Shoji
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 01.10.2005
Subjects
Online AccessGet full text

Cover

Loading…
Abstract CD14, a high-affinity receptor for lipopolysaccharide (LPS), is a glycoprotein expressed on the surface membranes of monocytes/macrophages. We have identified a previously unknown form of soluble CD14, named soluble CD14 subtype (sCD14-ST), that is increased in patients with sepsis. To measure sCD14-ST concentrations in plasma, we prepared anti-sCD14-ST antibodies and developed an enzyme immunoassay (EIA) for this soluble form of CD14. With this assay, quantitative measurements are available within 4h, and we compared the levels of sCD14-ST in plasma from normal subjects (healthy controls), patients with systemic inflammatory response syndrome (SIRS), and sepsis patients. The level of sCD14-ST in subjects with sepsis was much higher than the levels in subjects with SIRS and the healthy controls. Additionally, when a subject's sCD14-ST level was used as a diagnostic marker for sepsis, the area under the receiver operating characteristic (ROC) curve was 0.817, thereby demonstrating that elevated sCD14-ST levels were a better marker for sepsis than the other molecular markers we tested. sCD14-ST levels also correlated with procalcitonin (PCT) levels and with sequential organ failure assessment (SOFA) scores. Finally, changes in sCD14-ST concentration correlated with the severity of sepsis. Taken together, these results indicate that sCD14-ST is a useful marker for the rapid diagnosis of sepsis and for monitoring the severity of the disease.
AbstractList CD14, a high-affinity receptor for lipopolysaccharide (LPS), is a glycoprotein expressed on the surface membranes of monocytes/macrophages. We have identified a previously unknown form of soluble CD14, named soluble CD14 subtype (sCD14-ST), that is increased in patients with sepsis. To measure sCD14-ST concentrations in plasma, we prepared anti-sCD14-ST antibodies and developed an enzyme immunoassay (EIA) for this soluble form of CD14. With this assay, quantitative measurements are available within 4h, and we compared the levels of sCD14-ST in plasma from normal subjects (healthy controls), patients with systemic inflammatory response syndrome (SIRS), and sepsis patients. The level of sCD14-ST in subjects with sepsis was much higher than the levels in subjects with SIRS and the healthy controls. Additionally, when a subject's sCD14-ST level was used as a diagnostic marker for sepsis, the area under the receiver operating characteristic (ROC) curve was 0.817, thereby demonstrating that elevated sCD14-ST levels were a better marker for sepsis than the other molecular markers we tested. sCD14-ST levels also correlated with procalcitonin (PCT) levels and with sequential organ failure assessment (SOFA) scores. Finally, changes in sCD14-ST concentration correlated with the severity of sepsis. Taken together, these results indicate that sCD14-ST is a useful marker for the rapid diagnosis of sepsis and for monitoring the severity of the disease.
CD14, a high-affinity receptor for lipopolysaccharide (LPS), is a glycoprotein expressed on the surface membranes of monocytes/macrophages. We have identified a previously unknown form of soluble CD14, named soluble CD14 subtype (sCD14-ST), that is increased in patients with sepsis. To measure sCD14-ST concentrations in plasma, we prepared anti-sCD14-ST antibodies and developed an enzyme immunoassay (EIA) for this soluble form of CD14. With this assay, quantitative measurements are available within 4 h, and we compared the levels of sCD14-ST in plasma from normal subjects (healthy controls), patients with systemic inflammatory response syndrome (SIRS), and sepsis patients. The level of sCD14-ST in subjects with sepsis was much higher than the levels in subjects with SIRS and the healthy controls. Additionally, when a subject's sCD14-ST level was used as a diagnostic marker for sepsis, the area under the receiver operating characteristic (ROC) curve was 0.817, thereby demonstrating that elevated sCD14-ST levels were a better marker for sepsis than the other molecular markers we tested. sCD14-ST levels also correlated with procalcitonin (PCT) levels and with sequential organ failure assessment (SOFA) scores. Finally, changes in sCD14-ST concentration correlated with the severity of sepsis. Taken together, these results indicate that sCD14-ST is a useful marker for the rapid diagnosis of sepsis and for monitoring the severity of the disease.
CD14, a high-affinity receptor for lipopolysaccharide (LPS), is a glycoprotein expressed on the surface membranes of monocytes/macrophages. We have identified a previously unknown form of soluble CD14, named soluble CD14 subtype (sCD14-ST), that is increased in patients with sepsis. To measure sCD14-ST concentrations in plasma, we prepared anti-sCD14-ST antibodies and developed an enzyme immunoassay (EIA) for this soluble form of CD14. With this assay, quantitative measurements are available within 4 h, and we compared the levels of sCD14-ST in plasma from normal subjects (healthy controls), patients with systemic inflammatory response syndrome (SIRS), and sepsis patients. The level of sCD14-ST in subjects with sepsis was much higher than the levels in subjects with SIRS and the healthy controls. Additionally, when a subject's sCD14-ST level was used as a diagnostic marker for sepsis, the area under the receiver operating characteristic (ROC) curve was 0.817, thereby demonstrating that elevated sCD14-ST levels were a better marker for sepsis than the other molecular markers we tested. sCD14-ST levels also correlated with procalcitonin (PCT) levels and with sequential organ failure assessment (SOFA) scores. Finally, changes in sCD14-ST concentration correlated with the severity of sepsis. Taken together, these results indicate that sCD14-ST is a useful marker for the rapid diagnosis of sepsis and for monitoring the severity of the disease.CD14, a high-affinity receptor for lipopolysaccharide (LPS), is a glycoprotein expressed on the surface membranes of monocytes/macrophages. We have identified a previously unknown form of soluble CD14, named soluble CD14 subtype (sCD14-ST), that is increased in patients with sepsis. To measure sCD14-ST concentrations in plasma, we prepared anti-sCD14-ST antibodies and developed an enzyme immunoassay (EIA) for this soluble form of CD14. With this assay, quantitative measurements are available within 4 h, and we compared the levels of sCD14-ST in plasma from normal subjects (healthy controls), patients with systemic inflammatory response syndrome (SIRS), and sepsis patients. The level of sCD14-ST in subjects with sepsis was much higher than the levels in subjects with SIRS and the healthy controls. Additionally, when a subject's sCD14-ST level was used as a diagnostic marker for sepsis, the area under the receiver operating characteristic (ROC) curve was 0.817, thereby demonstrating that elevated sCD14-ST levels were a better marker for sepsis than the other molecular markers we tested. sCD14-ST levels also correlated with procalcitonin (PCT) levels and with sequential organ failure assessment (SOFA) scores. Finally, changes in sCD14-ST concentration correlated with the severity of sepsis. Taken together, these results indicate that sCD14-ST is a useful marker for the rapid diagnosis of sepsis and for monitoring the severity of the disease.
Author Sato, Nobuhiro
Furusako, Shoji
Endo, Shigeatsu
Imai, Satoko
Miyata, Michiko
Suzuki, Yasushi
Takahashi, Gaku
Yaegashi, Yasunori
Shirakawa, Kamon
Kojika, Masahiro
Author_xml – sequence: 1
  givenname: Yasunori
  surname: Yaegashi
  fullname: Yaegashi, Yasunori
– sequence: 2
  givenname: Nobuhiro
  surname: Sato
  fullname: Sato, Nobuhiro
– sequence: 3
  givenname: Yasushi
  surname: Suzuki
  fullname: Suzuki, Yasushi
– sequence: 4
  givenname: Masahiro
  surname: Kojika
  fullname: Kojika, Masahiro
– sequence: 5
  givenname: Satoko
  surname: Imai
  fullname: Imai, Satoko
– sequence: 6
  givenname: Gaku
  surname: Takahashi
  fullname: Takahashi, Gaku
– sequence: 7
  givenname: Michiko
  surname: Miyata
  fullname: Miyata, Michiko
– sequence: 8
  givenname: Shigeatsu
  surname: Endo
  fullname: Endo, Shigeatsu
  email: sendo@iwate-med.ac.jp
– sequence: 9
  givenname: Kamon
  surname: Shirakawa
  fullname: Shirakawa, Kamon
– sequence: 10
  givenname: Shoji
  surname: Furusako
  fullname: Furusako, Shoji
BackLink https://cir.nii.ac.jp/crid/1571135650252594048$$DView record in CiNii
https://www.ncbi.nlm.nih.gov/pubmed/16258819$$D View this record in MEDLINE/PubMed
BookMark eNqFkc1v1DAQxS1URD_gD-CCfEDcAjOJPxJxQktpkVbiAhI3y3HGkqk3Weyk1f73eEnh0EN7sefwe_M0752zk3EaibHXCO8RQH_ICChVBSArEACVeMbOUDS60rqFkzI3Aqumxp-n7DznXwCoZdu-YKeo6jJgd8a2l7c2LnYO08gnzy0f6S4eeBhonIMPNPA8xaWPxDefUfC89PNhT9zmgu5suqHE_ZR4pn0O-SV77m3M9Or-v2A_vlx-31xX229XXzeftpUTSs2VgM75ppFWu96L1grpfYe2Jemgt53uEGzdS98qV87shVBoUdbCOtG3Xvnmgr1b9-7T9HuhPJtdyI5itCNNSzaq1QJBdk-CqGvsUEMB39yDS7-jwexTKNcdzL-gCqBXwKUp50TeuDD_jW1ONkSDYI6VmLUSUyoxx0qMKEp8oPy__BHN21UzhlCMji9KjdhIJaGWtewEiLZgH1eMSti3gZLJLtDoaAiJ3GyGKTxq0j1Qu1isnI03dHhC-wd0i7uW
CitedBy_id crossref_primary_10_1038_s41372_024_01973_9
crossref_primary_10_1007_s00508_015_0719_5
crossref_primary_10_4103_AZMJ_AZMJ_122_19
crossref_primary_10_1093_tropej_fmac001
crossref_primary_10_1016_j_dld_2019_05_025
crossref_primary_10_3390_biomedicines13030701
crossref_primary_10_1007_s13341_013_0347_5
crossref_primary_10_3390_diagnostics15020217
crossref_primary_10_1186_s13613_016_0160_6
crossref_primary_10_1016_j_cca_2016_11_036
crossref_primary_10_4103_jwas_jwas_132_24
crossref_primary_10_1186_s13613_015_0089_1
crossref_primary_10_5312_wjo_v14_i7_547
crossref_primary_10_23736_S0375_9393_20_14169_5
crossref_primary_10_1016_j_ccc_2019_08_001
crossref_primary_10_3390_diagnostics11010060
crossref_primary_10_5937_afmnai41_46406
crossref_primary_10_1186_s40560_019_0374_4
crossref_primary_10_1016_j_transproceed_2013_07_021
crossref_primary_10_1186_s13054_015_1032_4
crossref_primary_10_1515_JLM_2008_030
crossref_primary_10_18527_2500_2236_2023_10_1_70_90
crossref_primary_10_1371_journal_pone_0129159
crossref_primary_10_1186_cc12847
crossref_primary_10_1016_j_pepo_2013_06_011
crossref_primary_10_1039_C8LC01102H
crossref_primary_10_1016_j_rmed_2014_05_005
crossref_primary_10_1016_j_jiac_2016_04_002
crossref_primary_10_33878_2073_7556_2019_18_3_105_118
crossref_primary_10_3109_14767058_2012_717462
crossref_primary_10_5761_atcs_ra_15_00187
crossref_primary_10_1016_j_clinbiochem_2019_12_007
crossref_primary_10_1016_j_ijid_2020_10_030
crossref_primary_10_3390_biomedicines10102332
crossref_primary_10_1371_journal_pone_0053692
crossref_primary_10_1515_tjb_2018_0220
crossref_primary_10_1186_2110_5820_3_22
crossref_primary_10_1007_s00101_014_2347_2
crossref_primary_10_1080_00365513_2022_2031278
crossref_primary_10_1016_j_cca_2015_08_013
crossref_primary_10_1186_s12890_018_0740_3
crossref_primary_10_1177_0310057X1704500510
crossref_primary_10_2152_jmi_68_105
crossref_primary_10_1097_ALN_0000000000001522
crossref_primary_10_3389_fneur_2018_00058
crossref_primary_10_1515_jccm_2017_0001
crossref_primary_10_2147_IDR_S325635
crossref_primary_10_1097_MS9_0000000000001643
crossref_primary_10_33713_egetbd_950007
crossref_primary_10_1016_j_apjtb_2016_04_005
crossref_primary_10_1055_a_1303_5105
crossref_primary_10_37748_2686_9039_2022_3_2_1
crossref_primary_10_1001_jamapediatrics_2022_1647
crossref_primary_10_1186_s12879_023_08353_2
crossref_primary_10_23736_S0375_9393_20_13661_7
crossref_primary_10_1515_JLM_2008_030et
crossref_primary_10_1017_S1466252322000019
crossref_primary_10_25016_2541_7487_2018_0_4_59_67
crossref_primary_10_1371_journal_pone_0146020
crossref_primary_10_3923_ajbmb_2023_49_60
crossref_primary_10_1097_MS9_0000000000000426
crossref_primary_10_1007_s10156_011_0254_x
crossref_primary_10_1371_journal_pone_0133057
crossref_primary_10_1371_journal_pone_0175254
crossref_primary_10_1016_j_molimm_2018_06_006
crossref_primary_10_4155_ppa_13_3
crossref_primary_10_1016_j_cca_2016_06_030
crossref_primary_10_1016_j_ejccm_2017_02_001
crossref_primary_10_2169_internalmedicine_55_6524
crossref_primary_10_36488_cmac_2020_3_175_187
crossref_primary_10_3390_jfmk7040097
crossref_primary_10_3390_tropicalmed7110355
crossref_primary_10_3389_fneur_2024_1429354
crossref_primary_10_1016_j_biopha_2018_12_124
crossref_primary_10_1186_cc13700
crossref_primary_10_1016_j_burnso_2017_05_010
crossref_primary_10_1016_j_rbmo_2023_103622
crossref_primary_10_1016_j_jcrc_2014_06_014
crossref_primary_10_1155_2015_792572
crossref_primary_10_1007_s12026_018_8994_7
crossref_primary_10_1016_j_jiac_2020_11_013
crossref_primary_10_5005_jp_journals_10071_23741
crossref_primary_10_1097_SHK_0000000000001269
crossref_primary_10_1097_MD_0000000000002158
crossref_primary_10_1620_tjem_246_199
crossref_primary_10_1371_journal_pone_0273930
crossref_primary_10_1093_burnst_tkaa047
crossref_primary_10_21320_2500_2139_2019_12_4_461_467
crossref_primary_10_12688_hrbopenres_13633_1
crossref_primary_10_3393_ac_2022_00115_0016
crossref_primary_10_1007_s00005_016_0415_9
crossref_primary_10_1186_1471_2253_14_88
crossref_primary_10_1097_BRS_0000000000002376
crossref_primary_10_1248_bpb_29_1015
crossref_primary_10_1016_j_cca_2011_07_024
crossref_primary_10_1016_j_jiac_2013_07_005
crossref_primary_10_1097_CCE_0000000000000591
crossref_primary_10_1093_burnst_tkae080
crossref_primary_10_2144_btn_2020_0136
crossref_primary_10_1186_cc14053
crossref_primary_10_1002_jhbp_802
crossref_primary_10_1515_tjb_2018_0532
crossref_primary_10_1016_j_jiac_2018_10_015
crossref_primary_10_1007_s00540_012_1502_7
crossref_primary_10_1016_j_clineuro_2025_108767
crossref_primary_10_1186_s40560_017_0246_8
crossref_primary_10_51620_0869_2084_2022_67_8_471_475
crossref_primary_10_1016_j_burns_2013_08_024
crossref_primary_10_1186_s40635_021_00400_z
crossref_primary_10_1213_ANE_0000000000003738
crossref_primary_10_1080_14787210_2019_1584037
crossref_primary_10_3390_jcm13195991
crossref_primary_10_1097_EJA_0000000000001243
crossref_primary_10_1186_s13052_016_0268_1
crossref_primary_10_1038_s41598_022_06613_w
crossref_primary_10_7448_IAS_19_8_21487
crossref_primary_10_1111_febs_15552
crossref_primary_10_1007_s00101_017_0363_8
crossref_primary_10_3390_medicina58111504
crossref_primary_10_36290_vnl_2019_078
crossref_primary_10_1007_s12223_014_0346_y
crossref_primary_10_1017_cts_2023_538
crossref_primary_10_4236_ajmb_2014_44019
crossref_primary_10_47429_lmo_2024_14_2_111
crossref_primary_10_1093_postmj_qgad132
crossref_primary_10_1186_cc13183
crossref_primary_10_1016_j_ejim_2017_09_030
crossref_primary_10_1186_s13054_023_04367_z
crossref_primary_10_1186_s12865_020_00362_z
crossref_primary_10_1186_cc13070
crossref_primary_10_1371_journal_pone_0143971
crossref_primary_10_1186_s12879_019_4316_5
crossref_primary_10_5847_wjem_j_issn_1920_8642_2014_01_002
crossref_primary_10_1038_s41598_022_22096_1
crossref_primary_10_1371_journal_pone_0215791
crossref_primary_10_1007_s00101_017_0396_z
crossref_primary_10_1186_s40902_022_00353_7
crossref_primary_10_3390_jcm13237038
crossref_primary_10_1007_s00134_007_0626_y
crossref_primary_10_5604_01_3001_0016_0233
crossref_primary_10_3389_fmed_2023_1126982
crossref_primary_10_3109_14767058_2014_942627
crossref_primary_10_1016_j_cca_2015_06_026
crossref_primary_10_1111_aas_14291
crossref_primary_10_1016_j_cca_2020_09_014
crossref_primary_10_1186_s41100_017_0113_z
crossref_primary_10_3893_jjaam_23_27
crossref_primary_10_1016_j_clinbiochem_2014_04_014
crossref_primary_10_2217_bmm_2019_0183
crossref_primary_10_5493_wjem_v5_i2_50
crossref_primary_10_1136_bmjopen_2016_014305
crossref_primary_10_1016_j_jss_2022_04_072
crossref_primary_10_1016_j_clineuro_2019_105396
crossref_primary_10_1038_s41598_024_80686_7
crossref_primary_10_1080_14397595_2016_1246119
crossref_primary_10_1186_s12894_021_00906_4
crossref_primary_10_18527_2500_2236_2023_10_1_70_90_RU
crossref_primary_10_3109_14767058_2011_601923
crossref_primary_10_1186_s12879_016_2116_8
crossref_primary_10_17116_labs2017627_14
crossref_primary_10_1111_j_1744_9987_2006_00340_x
crossref_primary_10_1186_s10195_022_00644_9
crossref_primary_10_1016_j_cca_2017_12_045
crossref_primary_10_1097_MD_0000000000031895
crossref_primary_10_1186_s13054_024_05032_9
crossref_primary_10_1159_000538870
crossref_primary_10_1016_j_jss_2018_02_059
crossref_primary_10_1007_s00134_014_3514_2
crossref_primary_10_1038_s41598_023_48633_0
crossref_primary_10_12677_acm_2024_1441063
crossref_primary_10_1007_s10156_012_0435_2
crossref_primary_10_1186_s13104_024_06719_6
crossref_primary_10_3390_biomedicines9091076
crossref_primary_10_1016_j_cca_2015_07_025
crossref_primary_10_1515_CCLM_2011_145
crossref_primary_10_1016_j_jcrc_2017_04_008
crossref_primary_10_1038_s41598_024_66916_y
crossref_primary_10_20408_jti_2023_0061
crossref_primary_10_1016_j_cca_2018_08_032
crossref_primary_10_3904_kjim_2023_558
crossref_primary_10_1016_j_ajem_2017_12_038
crossref_primary_10_17116_terarkh2015871184_91
crossref_primary_10_1007_s11882_007_0067_2
crossref_primary_10_1038_s41598_022_09926_y
crossref_primary_10_1093_labmed_lmaa011
crossref_primary_10_3389_fmed_2024_1393843
crossref_primary_10_1016_j_cca_2014_11_012
crossref_primary_10_1080_14767058_2017_1366984
crossref_primary_10_1007_s12072_016_9753_2
crossref_primary_10_1007_s00414_012_0804_5
crossref_primary_10_1515_cclm_2013_0061
crossref_primary_10_1093_labmed_lmaa015
crossref_primary_10_3390_jpm15040125
crossref_primary_10_1016_j_jiac_2015_04_011
crossref_primary_10_1016_j_molimm_2016_11_012
crossref_primary_10_1371_journal_pone_0206089
crossref_primary_10_4266_acc_2022_00150
crossref_primary_10_1038_s41598_020_66121_7
crossref_primary_10_3390_children11030350
crossref_primary_10_1016_j_jinf_2015_09_007
crossref_primary_10_1093_labmed_lmz005
crossref_primary_10_1128_JCM_03052_14
crossref_primary_10_1016_j_forsciint_2019_03_034
crossref_primary_10_1016_j_ijid_2020_03_057
crossref_primary_10_1016_j_cca_2019_09_012
Cites_doi 10.4049/jimmunol.147.5.1567
10.1093/nar/16.9.4173
10.1097/00003246-199206000-00025
10.1126/science.1698311
10.1016/0022-1759(92)90289-6
10.1051/vetres:2003006
10.1007/s00134-004-2210-z
10.1016/0140-6736(93)90277-N
10.1097/00003246-200008000-00019
10.1093/infdis/171.3.639
10.1182/blood.V92.6.2084.418k26_2084_2092
10.1164/ajrccm.155.3.9117029
10.1111/j.1365-2249.1994.tb06222.x
10.1093/infdis/173.3.661
10.1002/eji.1830250244
ContentType Journal Article
Copyright 2005 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases
Copyright_xml – notice: 2005 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases
DBID RYH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
C1K
7X8
DOI 10.1007/s10156-005-0400-4
DatabaseName CiNii Complete
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Bacteriology Abstracts (Microbiology B)
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Bacteriology Abstracts (Microbiology B)
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList

Bacteriology Abstracts (Microbiology B)
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1437-7780
EndPage 238
ExternalDocumentID 16258819
10_1007_s10156_005_0400_4
10016776293
S1341321X05709764
Genre Evaluation Studies
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--M
-Y2
-~C
.1-
.55
.86
.FO
.~1
0R~
0VY
1N0
1P~
1SB
1~.
2.D
28-
29K
2JY
2P1
2VQ
2~H
30V
4.4
408
409
40D
457
4G.
53G
5GY
5QI
5VS
67Z
6NX
7-5
8P~
8TC
8UJ
95.
95~
AAAJQ
AAEDT
AAEDW
AAIAL
AAIKJ
AAKOC
AALRI
AANXM
AAOAW
AAQFI
AARHV
AATTM
AAXKI
AAXUO
AAYWO
AAYZH
ABFSG
ABJNI
ABMAC
ABMNI
ABMZM
ABQSL
ABXDB
ACDAQ
ACGFS
ACIEU
ACOMO
ACRLP
ACSTC
ACVFH
ADBBV
ADCNI
ADEZE
ADHKG
ADIMF
ADKPE
ADQRH
ADRFC
ADVLN
AEBSH
AEFIE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AEZWR
AFBBN
AFEXP
AFHIU
AFLOW
AFPUW
AFRHN
AFTJW
AFWTZ
AFXIZ
AGCQF
AGGDS
AGHFR
AGJBK
AGQPQ
AGUBO
AHBYD
AHKAY
AHSBF
AHWEU
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AIXLP
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMRAJ
ANKPU
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
BA0
BBWZM
BGNMA
BKOJK
BLXMC
BNPGV
CAG
CJTIS
COF
CS3
CSCUP
D-I
DL5
EBS
EFJIC
EFKBS
EJD
EMOBN
EN4
F5P
FDB
FEDTE
FIRID
FYGXN
GBLVA
GQ8
GXS
H13
HF~
HG5
HG6
HMJXF
HVGLF
HZ~
I09
IHE
IXC
IXE
IZIGR
IZQ
I~X
KDC
KOM
KOW
KPH
LAS
M41
M4Y
MA-
MO0
N2Q
N9A
NB0
NDZJH
NU0
O9-
O93
O9G
O9I
OAM
OAUVE
OC~
P-8
P-9
P19
P2P
P9S
PC.
PT5
QOK
QOS
R4E
R89
R9I
RNI
ROL
RPX
RRX
RSV
RZK
S1Z
S26
S27
S28
S37
S3B
SDE
SDH
SDM
SMD
SOJ
SPCBC
SSH
SSZ
SV3
T13
T16
T5K
TSK
TSV
TT1
TUC
U2A
VC2
WJK
WK8
X7M
Z45
Z5R
~A9
~EX
~G-
-5E
-5G
-BR
0SF
AACTN
AAIAV
ABLVK
ABTEG
ABYKQ
ADINQ
AFKWA
AFNRJ
AHPSJ
AJBFU
AJOXV
AMFUW
EFLBG
GQ6
NCXOZ
RIG
SSI
SZN
Z7U
Z82
Z87
Z8O
Z8V
Z91
AFCTW
AGRNS
RYH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
C1K
7X8
ID FETCH-LOGICAL-c466t-409cf335a7cbf48a45ff91a8e5c0ba97910a2b5f86c100b4461a1524ac4b8f6f3
IEDL.DBID AIKHN
ISSN 1341-321X
IngestDate Fri Jul 11 05:07:24 EDT 2025
Mon Jul 21 09:46:11 EDT 2025
Wed Feb 19 02:43:24 EST 2025
Thu Apr 24 23:03:44 EDT 2025
Tue Jul 01 02:23:16 EDT 2025
Thu Jun 26 23:09:38 EDT 2025
Fri Feb 23 02:38:58 EST 2024
Tue Aug 26 16:59:28 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords SIRS
Sepsis
CD14
Diagnosis
EIA
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c466t-409cf335a7cbf48a45ff91a8e5c0ba97910a2b5f86c100b4461a1524ac4b8f6f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
ORCID 0000-0002-7296-8892
PMID 16258819
PQID 17219170
PQPubID 23462
PageCount 5
ParticipantIDs proquest_miscellaneous_68741059
proquest_miscellaneous_17219170
pubmed_primary_16258819
crossref_citationtrail_10_1007_s10156_005_0400_4
crossref_primary_10_1007_s10156_005_0400_4
nii_cinii_1571135650252594048
elsevier_sciencedirect_doi_10_1007_s10156_005_0400_4
elsevier_clinicalkey_doi_10_1007_s10156_005_0400_4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2005-Oct
PublicationDateYYYYMMDD 2005-10-01
PublicationDate_xml – month: 10
  year: 2005
  text: 2005-Oct
PublicationDecade 2000
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
PublicationTitleAlternate J. Infect. Chemother
PublicationTitle_FL J. Infect. Chemother
PublicationYear 2005
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
References Dellinger, Carlet, Masur, Gerlach, Calandra, Cohen (bib0080) 2004; 30
Lee, Paape, Zhao (bib0050) 2003; 34
Golenbock, Bach, Lichenstein, Juan, Tadavarthy, Moldow (bib0015) 1995; 125
Landmann, Zimmerli, Sansano, Link, Hahn, Glauser (bib0025) 1995; 171
Landmann, Reber, Sansano, Zimmerli (bib0055) 1996; 173
Endo, Inada, Kasai, Takakuwa, Nakae, Kikuchi (bib0030) 1994; 84
Martin, Rubenfeld, Ruzinski, Goodman, Steinberg, Leturcq (bib0040) 1997; 155
Wright, Ramos, Tobias, Ulevitch, Mathison (bib0010) 1990; 249
Grunwald, Krüger, Westermann, Lukowsky, Ehlers, Shütt (bib0020) 1992; 155
Lien, Aukrust, Sundan, Muller, Froland, Espevik (bib0035) 1998; 92
Bazil, Strominger (bib0075) 1991; 147
Oliver, Hartmut, Michael, Andreas, Wilfried, Jörg (bib0085) 2000; 28
Nockher, Wigarnd, Schoeppe, Scherberich (bib0045) 1994; 96
Assicot, Gendrel, Carsin, Raymond, Guilbaud, Bohuon (bib0065) 1993; 341
Ferrero, Goyert (bib0005) 1988; 16
(bib0060) 1992; 20
Bufler, Stieger, Schuchmann, Hess, Krüger, Stelter (bib0070) 1995; 25
Holzheimer, Capel, Cavaillon, Cainzos, Frileux, Haupt (bib0090) 2000; 5
Lien (10.1007/s10156-005-0400-4_bib0035) 1998; 92
Lee (10.1007/s10156-005-0400-4_bib0050) 2003; 34
Ferrero (10.1007/s10156-005-0400-4_bib0005) 1988; 16
Bufler (10.1007/s10156-005-0400-4_bib0070) 1995; 25
Oliver (10.1007/s10156-005-0400-4_bib0085) 2000; 28
Dellinger (10.1007/s10156-005-0400-4_bib0080) 2004; 30
Endo (10.1007/s10156-005-0400-4_bib0030) 1994; 84
Martin (10.1007/s10156-005-0400-4_bib0040) 1997; 155
Assicot (10.1007/s10156-005-0400-4_bib0065) 1993; 341
(10.1007/s10156-005-0400-4_bib0060) 1992; 20
Wright (10.1007/s10156-005-0400-4_bib0010) 1990; 249
Grunwald (10.1007/s10156-005-0400-4_bib0020) 1992; 155
Bazil (10.1007/s10156-005-0400-4_bib0075) 1991; 147
Golenbock (10.1007/s10156-005-0400-4_bib0015) 1995; 125
Landmann (10.1007/s10156-005-0400-4_bib0025) 1995; 171
Holzheimer (10.1007/s10156-005-0400-4_bib0090) 2000; 5
Nockher (10.1007/s10156-005-0400-4_bib0045) 1994; 96
Landmann (10.1007/s10156-005-0400-4_bib0055) 1996; 173
References_xml – volume: 30
  start-page: 536
  year: 2004
  end-page: 555
  ident: bib0080
  article-title: Surviving sepsis campaign guidelines for management of severe sepsis and septic shock
  publication-title: Intensive Care Med
– volume: 125
  start-page: 662
  year: 1995
  end-page: 671
  ident: bib0015
  article-title: Soluble CD14 promotes LPS activation of CD14-deficient PNH monocytes and endothelial cells
  publication-title: J Lab Clin Med
– volume: 84
  start-page: 17
  year: 1994
  end-page: 25
  ident: bib0030
  article-title: Soluble CD14 (sCD14) levels in patients with multiple organ failure (MOF)
  publication-title: Res Commun Chem Pathol Pharmacol
– volume: 249
  start-page: 1431
  year: 1990
  end-page: 1433
  ident: bib0010
  article-title: CD14, a receptor for complex of lipopolysaccharide (LPS) and LPS binding protein
  publication-title: Science
– volume: 16
  start-page: 4173
  year: 1988
  ident: bib0005
  article-title: Nucleotide sequence of the gene encoding the monocyte differentiation antigen, CD14
  publication-title: Nucleic Acids Res
– volume: 173
  start-page: 661
  year: 1996
  end-page: 668
  ident: bib0055
  article-title: Function of soluble CD14 in serum from patients with septic shock
  publication-title: J Infect Dis
– volume: 28
  start-page: 2793
  year: 2000
  end-page: 2798
  ident: bib0085
  article-title: Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6
  publication-title: Crit Care Med
– volume: 341
  start-page: 515
  year: 1993
  end-page: 518
  ident: bib0065
  article-title: High serum procalcitonin concentrations in patients with sepsis and infection
  publication-title: Lancet
– volume: 147
  start-page: 1567
  year: 1991
  end-page: 1574
  ident: bib0075
  article-title: Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes
  publication-title: J Immunol
– volume: 155
  start-page: 225
  year: 1992
  end-page: 232
  ident: bib0020
  article-title: An enzyme-linked immunosorbent assay for the quantification of solubilized CD14 in biological fluids
  publication-title: J Immunol Methods
– volume: 20
  start-page: 864
  year: 1992
  end-page: 874
  ident: bib0060
  article-title: Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
  publication-title: Crit Care Med
– volume: 34
  start-page: 307
  year: 2003
  end-page: 316
  ident: bib0050
  article-title: Recombinant bovine CD14 reduces severity of experimental
  publication-title: Vet Res
– volume: 5
  start-page: 283
  year: 2000
  end-page: 294
  ident: bib0090
  article-title: Immunological surrogate parameters in a prognostic model for multi-organ failure and death
  publication-title: Eur J Med Res
– volume: 171
  start-page: 639
  year: 1995
  end-page: 644
  ident: bib0025
  article-title: Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock
  publication-title: J Infect Dis
– volume: 96
  start-page: 15
  year: 1994
  end-page: 19
  ident: bib0045
  article-title: Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus
  publication-title: Clin Exp Immunol
– volume: 155
  start-page: 937
  year: 1997
  end-page: 944
  ident: bib0040
  article-title: Relationship between soluble CD14, lipopolysaccharide binding protein, and the alveolar inflammatory response in patients with acute respiratory distress syndrome
  publication-title: Am J Respir Crit Care Med
– volume: 92
  start-page: 2084
  year: 1998
  end-page: 2092
  ident: bib0035
  article-title: Elevated levels of serum-soluble CD14 in human immunodefiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events
  publication-title: Blood
– volume: 25
  start-page: 604
  year: 1995
  end-page: 610
  ident: bib0070
  article-title: Soluble lipopolysaccharide receptor (CD14) released via two different mechanisms from human monocytes and CD14 transfectants
  publication-title: Eur J Immunol
– volume: 147
  start-page: 1567
  year: 1991
  ident: 10.1007/s10156-005-0400-4_bib0075
  article-title: Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes
  publication-title: J Immunol
  doi: 10.4049/jimmunol.147.5.1567
– volume: 16
  start-page: 4173
  year: 1988
  ident: 10.1007/s10156-005-0400-4_bib0005
  article-title: Nucleotide sequence of the gene encoding the monocyte differentiation antigen, CD14
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/16.9.4173
– volume: 20
  start-page: 864
  year: 1992
  ident: 10.1007/s10156-005-0400-4_bib0060
  article-title: Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
  publication-title: Crit Care Med
  doi: 10.1097/00003246-199206000-00025
– volume: 125
  start-page: 662
  year: 1995
  ident: 10.1007/s10156-005-0400-4_bib0015
  article-title: Soluble CD14 promotes LPS activation of CD14-deficient PNH monocytes and endothelial cells
  publication-title: J Lab Clin Med
– volume: 249
  start-page: 1431
  year: 1990
  ident: 10.1007/s10156-005-0400-4_bib0010
  article-title: CD14, a receptor for complex of lipopolysaccharide (LPS) and LPS binding protein
  publication-title: Science
  doi: 10.1126/science.1698311
– volume: 155
  start-page: 225
  year: 1992
  ident: 10.1007/s10156-005-0400-4_bib0020
  article-title: An enzyme-linked immunosorbent assay for the quantification of solubilized CD14 in biological fluids
  publication-title: J Immunol Methods
  doi: 10.1016/0022-1759(92)90289-6
– volume: 5
  start-page: 283
  year: 2000
  ident: 10.1007/s10156-005-0400-4_bib0090
  article-title: Immunological surrogate parameters in a prognostic model for multi-organ failure and death
  publication-title: Eur J Med Res
– volume: 84
  start-page: 17
  year: 1994
  ident: 10.1007/s10156-005-0400-4_bib0030
  article-title: Soluble CD14 (sCD14) levels in patients with multiple organ failure (MOF)
  publication-title: Res Commun Chem Pathol Pharmacol
– volume: 34
  start-page: 307
  year: 2003
  ident: 10.1007/s10156-005-0400-4_bib0050
  article-title: Recombinant bovine CD14 reduces severity of experimental Escherichia coli mastitis in mice
  publication-title: Vet Res
  doi: 10.1051/vetres:2003006
– volume: 30
  start-page: 536
  year: 2004
  ident: 10.1007/s10156-005-0400-4_bib0080
  article-title: Surviving sepsis campaign guidelines for management of severe sepsis and septic shock
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-004-2210-z
– volume: 341
  start-page: 515
  year: 1993
  ident: 10.1007/s10156-005-0400-4_bib0065
  article-title: High serum procalcitonin concentrations in patients with sepsis and infection
  publication-title: Lancet
  doi: 10.1016/0140-6736(93)90277-N
– volume: 28
  start-page: 2793
  year: 2000
  ident: 10.1007/s10156-005-0400-4_bib0085
  article-title: Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6
  publication-title: Crit Care Med
  doi: 10.1097/00003246-200008000-00019
– volume: 171
  start-page: 639
  year: 1995
  ident: 10.1007/s10156-005-0400-4_bib0025
  article-title: Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock
  publication-title: J Infect Dis
  doi: 10.1093/infdis/171.3.639
– volume: 92
  start-page: 2084
  year: 1998
  ident: 10.1007/s10156-005-0400-4_bib0035
  article-title: Elevated levels of serum-soluble CD14 in human immunodefiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events
  publication-title: Blood
  doi: 10.1182/blood.V92.6.2084.418k26_2084_2092
– volume: 155
  start-page: 937
  year: 1997
  ident: 10.1007/s10156-005-0400-4_bib0040
  article-title: Relationship between soluble CD14, lipopolysaccharide binding protein, and the alveolar inflammatory response in patients with acute respiratory distress syndrome
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/ajrccm.155.3.9117029
– volume: 96
  start-page: 15
  year: 1994
  ident: 10.1007/s10156-005-0400-4_bib0045
  article-title: Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus
  publication-title: Clin Exp Immunol
  doi: 10.1111/j.1365-2249.1994.tb06222.x
– volume: 173
  start-page: 661
  year: 1996
  ident: 10.1007/s10156-005-0400-4_bib0055
  article-title: Function of soluble CD14 in serum from patients with septic shock
  publication-title: J Infect Dis
  doi: 10.1093/infdis/173.3.661
– volume: 25
  start-page: 604
  year: 1995
  ident: 10.1007/s10156-005-0400-4_bib0070
  article-title: Soluble lipopolysaccharide receptor (CD14) released via two different mechanisms from human monocytes and CD14 transfectants
  publication-title: Eur J Immunol
  doi: 10.1002/eji.1830250244
SSID ssj0017588
Score 2.2064605
Snippet CD14, a high-affinity receptor for lipopolysaccharide (LPS), is a glycoprotein expressed on the surface membranes of monocytes/macrophages. We have identified...
SourceID proquest
pubmed
crossref
nii
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 234
SubjectTerms Aged
Biomarkers - blood
CD14
Diagnosis
EIA
Humans
Immunoenzyme Techniques - methods
Lipopolysaccharide Receptors - blood
Male
ROC Curve
Sepsis
Sepsis - diagnosis
Severity of Illness Index
SIRS
Systemic Inflammatory Response Syndrome - diagnosis
Title Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1341321X05709764
https://dx.doi.org/10.1007/s10156-005-0400-4
https://cir.nii.ac.jp/crid/1571135650252594048
https://www.ncbi.nlm.nih.gov/pubmed/16258819
https://www.proquest.com/docview/17219170
https://www.proquest.com/docview/68741059
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07b9swED7EydKl6Ltum5RDkaGIalGkJGoM3ATuKwjQBPBGkBQJCHBlI7IHL_ntubMkGx2cAl00CDyAOh7vvhPvPgJ8KkXwymZFVMpURcQoh3suqMgpT72OvJQ5NTj_usomt_L7NJ0ewLjvhaGyys73tz594627N6NOm6NFVY1-ExWZSPgUEUeMQVUO4CgRRYamfXT-7cfkanuYgJB40xGH4yMS6A832w46TGAiouMka47kvvA0qKtqPwjdBKPLZ_C0Q5HsvJ3oczjw9Qs4vW5pqNdn7GbXVdWcsVN2vSOoXr-Enxdbim82D8wwhNazNavKtnLIl4wM0s48G3_lkjUrSz9qmWlw6B8q57ljCHVZ4xdN1byC28uLm_Ek6m5ViJzMsiUmjIULQqQmdzZIZWQaQsGN8qmLrSlyxA8msWlQmUMVWUwXucEgL42TVoUsiNdwWM9r_xZYjmsbuC2LNCfiQFHYJBjBXTCypNb_IcS9MrXrKMfp5ouZ3pElk_416l-T_rUcwuetyKLl23hscNKvkO4bSdH1aYwGjwnJrdBflvYvsWM0AfwMevI051wgFkbEiPmjRDc4hI-9cWjcoXTsYmo_XzWakmxMiuP9IzKVU7VtMYQ3rVXtPh3TU4Wg7d3_Tfo9POmpZmP-AQ6Xdyt_jCBqaU9g8OWen3Rb5QFQTxFp
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9tAEB0BPbQX1EIpKQX2gDhUmHjjtb0-VikobQNCapByW-2udyVLwYlwcsilv52Z2E7UQ6jUiw_WrGSP5-ONd-YtwEUeeSdNkgW5iGVAjHLoc14GVjqadeS5SGnA-e4-GTyKn-N4vAP9dhaG2iqb2F_H9FW0bu50G212Z0XR_U1UZFGPjxFxhJhUxS68Eei-5J3Xf9Z9HpgeV4dPknRA4u3WZj0_h-VLQGScZMuB2Jacdsui2A5BV6no9j3sNxiSfasf8wPsuPIALh9qEurlFRttZqqqK3bJHjb01MtDGN6sCb7Z1DPNEFhPlqzI674hlzMyRzNxrP-dC1YtDP2mZbpC0Sdq5nlmCHRZ5WZVUX2Ex9ubUX8QNGcqBFYkyRzLxcz6KIp1ao0XUovY-4xr6WIbGp2liB50z8ReJhZVZLBY5BpTvNBWGOkTHx3BXjkt3TGwFL-s5ybP4pRoA6PM9LyOuPVa5DT434GwVaayDeE4nXsxURuqZNK_Qv0r0r8SHfi6XjKr2TZeE-61X0i1Y6QY-BTmgtcWifWiv-zsX8tO0QTwNejK45TzCJEw4kWsHgUGwQ6ct8ah0D9p00WXbrqoFJXYWBKH2yUSmVKvbdaBT7VVbV4di1OJkO3z_z30ObwdjO6Gavjj_tcJvGtJZ0P-Bfbmzwt3inBqbs5W7vICfJoSLQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+a+newly+identified+soluble+CD14+subtype+as+a+marker+for+sepsis&rft.jtitle=Journal+of+infection+and+chemotherapy+%3A+official+journal+of+the+Japan+Society+of+Chemotherapy&rft.au=Yaegashi%2C+Yasunori&rft.au=Sato%2C+Nobuhiro&rft.au=Suzuki%2C+Yasushi&rft.au=Kojika%2C+Masahiro&rft.date=2005-10-01&rft.pub=Elsevier+Ltd&rft.issn=1341-321X&rft.volume=11&rft.issue=5&rft.spage=234&rft.epage=238&rft_id=info:doi/10.1007%2Fs10156-005-0400-4&rft.externalDocID=S1341321X05709764
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1341-321X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1341-321X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1341-321X&client=summon